-transparent.png){kind=logo}
Menogaril, a semisynthetic anthracycline antibiotic, was administered to patients with metastatic adenocarcinoma of the prostate. Forty-five patients with measurable disease and 45 patients with evaluable disease received 150-200 mg/m2 over 1 hour every 28 days. There were three partial responses (PR) among 87 patients evaluable for response. Myelosuppression was dose limiting. There were two deaths related to leukepenia. Other toxicities included phlebitis, alopecia, nausea and vomiting. One patient developed acute nonlymphocytic leukemia. Menogaril at these doses and schedule is toxic and has no significant antitumor activity in metastatic adenocarcinoma of the prostate.
S A Taylor, and
B A Blumenstein, and
R L Stephens, and
E D Crawford, and
B Pistone, and
J B Hill
February 1991,
Investigational new drugs,
S A Taylor, and
B A Blumenstein, and
R L Stephens, and
E D Crawford, and
B Pistone, and
J B Hill
January 1999,
Investigational new drugs,
S A Taylor, and
B A Blumenstein, and
R L Stephens, and
E D Crawford, and
B Pistone, and
J B Hill
August 1990,
Investigational new drugs,
S A Taylor, and
B A Blumenstein, and
R L Stephens, and
E D Crawford, and
B Pistone, and
J B Hill
January 1990,
Investigational new drugs,
S A Taylor, and
B A Blumenstein, and
R L Stephens, and
E D Crawford, and
B Pistone, and
J B Hill
December 1987,
Cancer treatment reports,
S A Taylor, and
B A Blumenstein, and
R L Stephens, and
E D Crawford, and
B Pistone, and
J B Hill
January 1994,
Investigational new drugs,
S A Taylor, and
B A Blumenstein, and
R L Stephens, and
E D Crawford, and
B Pistone, and
J B Hill
April 1979,
Cancer treatment reports,
S A Taylor, and
B A Blumenstein, and
R L Stephens, and
E D Crawford, and
B Pistone, and
J B Hill
November 1993,
Investigational new drugs,
S A Taylor, and
B A Blumenstein, and
R L Stephens, and
E D Crawford, and
B Pistone, and
J B Hill
August 1996,
American journal of clinical oncology,
S A Taylor, and
B A Blumenstein, and
R L Stephens, and
E D Crawford, and
B Pistone, and
J B Hill
February 1994,
American journal of clinical oncology,
